舒眠胶囊联合艾司西酞普兰治疗抑郁症睡眠障碍的疗效观察  

Efficacy of Shu Mian Capsule Combined with Escitalopram in the Treatment of Sleep Disorder of Depressive Patients

作　　者：刘伟杰[1] 陈永新[1] 张瑞岭[2] LIU Wei-jie;CHEN Yong-xin;ZHANG Rui-ling(Department of Pharmacy,The Second Affiliated Hospital of Xinxiang Medical University,Xinxiang 453002,China;Department of psychiatry, The Second Affiliated Hospital of Xinxiang Medical University,Xinxiang 453002,China)

机构地区：[1]河南省新乡医学院第二附属医院药学部,新乡453002 [2]河南省新乡医学院第二附属医院精神科,新乡453002

出　　处：《海峡药学》2018年第12期63-65,共3页Strait Pharmaceutical Journal

基　　金：河南省卫生厅卫生政策研究课题(No.YWZY201348)

摘　　要：目的观察舒眠胶囊联合艾司西酞普兰治疗抑郁症睡眠障碍的临床疗效及安全性。方法将我院98例抑郁症睡眠障碍患者采用随机双盲对照法分为对照组和治疗组,每组49例。对照组给予艾司西酞普兰治疗联合艾司唑仑,治疗组给予舒眠胶囊联合艾司西酞普兰治疗,治疗8周。于治疗前和治疗2、4、8周后观察并比较两组患者的汉密尔顿抑郁量表(HAMD)、匹兹堡睡眠质量指数量表(PSQI)、不良反应量表(TESS)和生活质量指数量表(QL-I)评价总体疗效及安全性。结果对照组和治疗组的有效率分别为89.80%和91.84%。与治疗前相比较,治疗后2、4、8周两组的HAMD评分、PSQI评分和QL-I评分均有明显改变,从治疗第2周末期起,治疗组的HAMD和PSQI的评分较对照组无明显差异,而治疗组的QL-I评分较对照组明显提高(P<0.05或0.01)。对照组的不良反应总数9例(18.36%),治疗组的不良反应4例(8.16%),两组比较有显著性差异。结论舒眠胶囊联合艾司西酞普兰治疗抑郁症睡眠障碍的疗效确切,改善睡眠,提高患者的生活质量,减少不良反应。OBJECTIVE To observe the clinical efficacy and safety of Shu Mian capsule combine with escitalopram in the treatment of sleep disorder of depressive patients.METHODS Totally 98 cases with depression combined with sleep disorder were randomly divided into treatment and control groups with 49 cases in each group.Escitalopram combine with estazolam were taken oral in control group for 8 weeks.Observation group took ShuMian capsule combined with escitalopram for 8 weeks.The Clinical efficacy and safety were assessed with the hamilton depression scale(HAMD),pittsburgh sleep quality index(PSQI),treatment emergent symptom scale(TESS)and quality of life index(QL-I) before and at the end of the 2,4,8 weeks of the treatment.RESULTS The results showed that the effective rate of control group was 89.80% and the effective rate of treatment group was 91.84% after 8 weeks interference with no significant difference between the groups.After 2,4,8 weeks of the treatment,the score of HAMD,PSQI and QL-I changed remarkably in both groups.Compare with the control group,HAMD and PSQI score of the treatment group were no significantly changed,QL-I score of the treatment group were significantly increased from the second treatment(P<0.05 or 0.01).The adverse rate of the control group was 18.36%,the adverse rate of the treatment group was 8.16% with significant difference between treatment and control groups.CONCLUSION The results suggest ShuMian capsule combined with escitalopram has good efficacy,improve the quality of sleep and life,less side effects in the treatment of sleep disorder of depressive patients.

关 键 词：舒眠胶囊 艾司唑仑 艾司西酞普兰 抑郁症 睡眠障碍 

分 类 号：R969.4[医药卫生—药理学]